These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20203643)

  • 41. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.
    Marrero JA; Fontana RJ; Su GL; Conjeevaram HS; Emick DM; Lok AS
    Hepatology; 2002 Dec; 36(6):1349-54. PubMed ID: 12447858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.
    Bedogni G; Miglioli L; Masutti F; Tiribelli C; Marchesini G; Bellentani S
    Hepatology; 2005 Jul; 42(1):44-52. PubMed ID: 15895401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pediatric nonalcoholic fatty liver disease.
    Lerret SM; Skelton JA
    Gastroenterol Nurs; 2008; 31(2):115-9. PubMed ID: 18391799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome.
    Sanyal AJ; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Stravitz RT; Mills AS
    Am J Gastroenterol; 2003 Sep; 98(9):2064-71. PubMed ID: 14499789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonalcoholic fatty liver disease.
    Yu AS; Keeffe EB
    Rev Gastroenterol Disord; 2002; 2(1):11-9. PubMed ID: 12122975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
    Mindikoglu AL; Regev A; Casanova-Romero PY; Bejarano PA; Martinez EJ; Tzakis AG; Schiff ER
    Transplant Proc; 2006 Jun; 38(5):1440-4. PubMed ID: 16797327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonalcoholic fatty liver disease: from clinical recognition to treatment.
    Sevastianos VA; Hadziyannis SJ
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):59-79. PubMed ID: 19072371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonalcoholic fatty liver disease.
    Adams LA; Lindor KD
    Ann Epidemiol; 2007 Nov; 17(11):863-9. PubMed ID: 17728149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Brzozowska MM; Ostapowicz G; Weltman MD
    J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).
    Ali R; Cusi K
    Ann Med; 2009; 41(4):265-78. PubMed ID: 19353360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonalcoholic fatty liver disease.
    Angulo P
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():52-6. PubMed ID: 17471859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis?
    Duclos-Vallée JC; Yilmaz F; Johanet C; Roque-Afonso AM; Gigou M; Trichet C; Féray C; Ballot E; Dussaix E; Castaing D; Bismuth H; Samuel D; Guettier C
    Clin Transplant; 2005 Oct; 19(5):591-9. PubMed ID: 16146549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spectrum of histological features in non-alcoholic fatty liver disease.
    Vasdev N; Kakati AG; Saigal S; Nayak NC
    Natl Med J India; 2007; 20(6):282-7. PubMed ID: 18335793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation.
    Machicao VI; Krishna M; Bonatti H; Aqel BA; Nguyen JH; Weigand SD; Rosser BG; Hughes C; Dickson RC
    Liver Transpl; 2004 May; 10(5):599-606. PubMed ID: 15108251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation.
    Patil DT; Yerian LM
    Liver Transpl; 2012 Oct; 18(10):1147-53. PubMed ID: 22740341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiology of non-alcoholic fatty liver disease in China.
    Fan JG; Farrell GC
    J Hepatol; 2009 Jan; 50(1):204-10. PubMed ID: 19014878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.
    Uchil D; Pipalia D; Chawla M; Patel R; Maniar S; Narayani ; Juneja A
    J Assoc Physicians India; 2009 Mar; 57():201-4. PubMed ID: 19588647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.